Single-dose, virus-vectored vaccine protection against Yersinia pestis challenge: CD4+ cells are required at the time of challenge for optimal protection

Vaccine

Volumn 26, Issue 50, 2008, Pages 6329-6337

  Chattopadhyay, Anasuya ^a   Park, Steven ^b   Delmas, Guillaume ^b   Suresh, Rema ^b   Senina, Svetlana ^b   Perlin, David S ^b   Rose, John K ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

CD4+ cells; Vesicular stomatitis virus; Yersinia pestis

Indexed keywords

BACTERIAL PROTEIN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; PLAGUE VACCINE; PROTEIN LCRV1; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; GENOME; IMMUNE RESPONSE; MOUSE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; VESICULAR STOMATITIS VIRUS; YERSINIA PESTIS; YERSINIOSIS;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BASE SEQUENCE; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; FEMALE; GENETIC VECTORS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PLAGUE; PLAGUE VACCINE; PORE FORMING CYTOTOXIC PROTEINS; VACCINIA VIRUS; YERSINIA PESTIS;

EID: 55749094658     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.09.031     Document Type: Article

References (63)

1. Perry R.D., and Fetherston J.D. Yersinia pestis-etiologic agent of plague. Clin Microbiol Rev 10 1 (1997) 35-66
2. Meyer K.F. Pneumonic plague. Bacteriol Rev 25 (1961) 249-261
3. Galimand M., Guiyoule A., Gerbaud G., Rasoamanana B., Chanteau S., Carniel E., et al. Multidrug resistance in Yersinia pestis mediated by a transferable plasmid. N Engl J Med 337 10 (1997) 677-680
4. Hinnebusch B.J., Rosso M.L., Schwan T.G., and Carniel E. High-frequency conjugative transfer of antibiotic resistance genes to Yersinia pestis in the flea midgut. Mol Microbiol 46 2 (2002) 349-354
5. Inglesby T.V., Dennis D.T., Henderson D.A., Bartlett J.G., Ascher M.S., Eitzen E., et al. Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 283 17 (2000) 2281-2290
6. Smiley S.T. Current challenges in the development of vaccines for pneumonic plague. Expert Rev Vaccines 7 2 (2008) 209-221
7. Titball R.W., and Williamson E.D. Yersinia pestis (plague) vaccines. Expert Opin Biol Ther 4 6 (2004) 965-973
8. Benner G.E., Andrews G.P., Byrne W.R., Strachan S.D., Sample A.K., Heath D.G., et al. Immune response to Yersinia outer proteins and other Yersinia pestis antigens after experimental plague infection in mice. Infect Immun 67 4 (1999) 1922-1928
9. Philipovskiy A.V., Cowan C., Wulff-Strobel C.R., Burnett S.H., Kerschen E.J., Cohen D.A., et al. Antibody against V antigen prevents Yop-dependent growth of Yersinia pestis. Infect Immun 73 3 (2005) 1532-1542
10. Heath D.G., Anderson Jr. G.W., Mauro J.M., Welkos S.L., Andrews G.P., Adamovicz J., et al. Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine. Vaccine 16 11-12 (1998) 1131-1137
11. Anderson Jr. G.W., Leary S.E., Williamson E.D., Titball R.W., Welkos S.L., Worsham P.L., et al. Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis. Infect Immun 64 11 (1996) 4580-4585
12. Eyles J.E., Williamson E.D., Spiers I.D., and Alpar H.O. Protection studies following bronchopulmonary and intramuscular immunisation with Yersinia pestis F1 and V subunit vaccines coencapsulated in biodegradable microspheres: a comparison of efficacy. Vaccine 18 28 (2000) 3266-3271
13. Leary S.E., Williamson E.D., Griffin K.F., Russell P., Eley S.M., and Titball R.W. Active immunization with recombinant V antigen from Yersinia pestis protects mice against plague. Infect Immun 63 8 (1995) 2854-2858
14. Powell B.S., Andrews G.P., Enama J.T., Jendrek S., Bolt C., Worsham P., et al. Design and testing for a nontagged F1-V fusion protein as vaccine antigen against bubonic and pneumonic plague. Biotechnol Prog 21 5 (2005) 1490-1510
15. Williamson E.D., Eley S.M., Griffin K.F., Green M., Russell P., Leary S.E., et al. A new improved sub-unit vaccine for plague: the basis of protection. FEMS Immunol Med Microbiol 12 3-4 (1995) 223-230
16. Williamson E.D., Eley S.M., Stagg A.J., Green M., Russell P., and Titball R.W. A sub-unit vaccine elicits IgG in serum, spleen cell cultures and bronchial washings and protects immunized animals against pneumonic plague. Vaccine 15 10 (1997) 1079-1084
17. Williamson E.D., Eley S.M., Stagg A.J., Green M., Russell P., and Titball R.W. A single dose sub-unit vaccine protects against pneumonic plague. Vaccine 19 4-5 (2000) 566-571
18. Williamson E.D., Sharp G.J., Eley S.M., Vesey P.M., Pepper T.C., Titball R.W., et al. Local and systemic immune response to a microencapsulated sub-unit vaccine for plague. Vaccine 14 17-18 (1996) 1613-1619
19. Pettersson J., Holmstrom A., Hill J., Leary S., Frithz-Lindsten E., von Euler-Matell A., et al. The V-antigen of Yersinia is surface exposed before target cell contact and involved in virulence protein translocation. Mol Microbiol 32 5 (1999) 961-976
20. Sarker M.R., Neyt C., Stainier I., and Cornelis G.R. The Yersinia Yop virulon: LcrV is required for extrusion of the translocators YopB and YopD. J Bacteriol 180 5 (1998) 1207-1214
21. Hill J., Leary S.E., Griffin K.F., Williamson E.D., and Titball R.W. Regions of Yersinia pestis V antigen that contribute to protection against plague identified by passive and active immunization. Infect Immun 65 11 (1997) 4476-4482
22. Hill J., Copse C., Leary S., Stagg A.J., Williamson E.D., and Titball R.W. Synergistic protection of mice against plague with monoclonal antibodies specific for the F1 and V antigens of Yersinia pestis. Infect Immun 71 4 (2003) 2234-2238
23. Motin V.L., Nakajima R., Smirnov G.B., and Brubaker R.R. Passive immunity to yersiniae mediated by anti-recombinant V antigen and protein A-V antigen fusion peptide. Infect Immun 62 10 (1994) 4192-4201
24. Palin A., Chattopadhyay A., Park S., Delmas G., Suresh R., Senina S., et al. An optimized vaccine vector based on recombinant vesicular stomatitis virus gives high-level, long-term protection against Yersinia pestis challenge. Vaccine 25 4 (2007) 741-750
25. Une T., and Brubaker R.R. Roles of V antigen in promoting virulence and immunity in yersiniae. J Immunol 133 4 (1984) 2226-2230
26. Wang S., Heilman D., Liu F., Giehl T., Joshi S., Huang X., et al. A DNA vaccine producing LcrV antigen in oligomers is effective in protecting mice from lethal mucosal challenge of plague. Vaccine 22 25-26 (2004) 3348-3357
27. Chiuchiolo M.J., Boyer J.L., Krause A., Senina S., Hackett N.R., and Crystal R.G. Protective immunity against respiratory tract challenge with Yersinia pestis in mice immunized with an adenovirus-based vaccine vector expressing V antigen. J Infect Dis 194 9 (2006) 1249-1257
28. Do Y., Park C.G., Kang Y.S., Park S.H., Lynch R.M., Lee H., et al. Broad T cell immunity to the LcrV virulence protein is induced by targeted delivery to DEC-205/CD205-positive mouse dendritic cells. Eur J Immunol 38 1 (2008) 20-29
29. Rose J.K., and Whitt M.A. Rhabdoviridae: the viruses and their replication. In: Knipe D.M., Howley P.M., Griffin D.E., Lamb R.A., Martin M.A., Roizman B., and Straus S.E. (Eds). Fields' virology (2001), Lippincott Williams and Wilkins, Philadelphia
30. Roberts A., Kretzschmar E., Perkins A.S., Forman J., Price R., Buonocore L., et al. Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge. J Virol 72 6 (1998) 4704-4711
31. Lawson N.D., Stillman E.A., Whitt M.A., and Rose J.K. Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci USA 92 10 (1995) 4477-4481
32. Schnell M.J., Buonocore L., Whitt M.A., and Rose J.K. The minimal conserved transcription stop-start signal promotes stable expression of a foreign gene in vesicular stomatitis virus. J Virol 70 4 (1996) 2318-2323
33. Egan M.A., Chong S.Y., Rose N.F., Megati S., Lopez K.J., Schadeck E.B., et al. Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes. AIDS Res Hum Retroviruses 20 9 (2004) 989-1004
34. Ramsburg E., Rose N.F., Marx P.A., Mefford M., Nixon D.F., Moretto W.J., et al. Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol. J Virol 78 8 (2004) 3930-3940
35. Rose N.F., Marx P.A., Luckay A., Nixon D.F., Moretto W.J., Donahoe S.M., et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 106 5 (2001) 539-549
36. Kretzschmar E., Buonocore L., Schnell M.J., and Rose J.K. High-efficiency incorporation of functional influenza virus glycoproteins into recombinant vesicular stomatitis viruses. J Virol 71 8 (1997) 5982-5989
37. Roberts A., Buonocore L., Price R., Forman J., and Rose J.K. Attenuated vesicular stomatitis viruses as vaccine vectors. J Virol 73 5 (1999) 3723-3732
38. Dietzschold B., Rupprecht C.E., Fu Z.F., and Koprowski H. Rhabdoviruses. In: Fields B.N., Knipe D.M., and Howley P.M. (Eds). Fields' virology (1996), Lippincott-Raven, Philadelphia 1137-1159
39. Zinkernagel R.M., Adler B., and Holland J.J. Cell-mediated immunity to vesicular stomatitis virus infections in mice. Exp Cell Biol 46 1-2 (1978) 53-70
40. Garbutt M., Liebscher R., Wahl-Jensen V., Jones S., Moller P., Wagner R., et al. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol 78 10 (2004) 5458-5465
41. Geisbert T.W., Jones S., Fritz E.A., Shurtleff A.C., Geisbert J.B., Liebscher R., et al. Development of a new vaccine for the prevention of lassa fever. PLOS Med 2 6 (2006) 537-545
42. Jones S.M., Feldmann H., Stroher U., Geisbert J.B., Fernando L., Grolla A., et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 11 7 (2005) 786-790
43. Kahn J.S., Roberts A., Weibel C., Buonocore L., and Rose J.K. Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge. J Virol 75 22 (2001) 11079-11087
44. Kapadia S.U., Rose J.K., Lamirande E., Vogel L., Subbarao K., and Roberts A. Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. Virology 340 2 (2005) 174-182
45. Natuk R.J., Cooper D., Guo M., Calderon P., Wright K.J., Nasar F., et al. Recombinant vesicular stomatitis virus vectors expressing herpes simplex virus type 2 gD elicit robust CD4+ Th1 immune responses and are protective in mouse and guinea pig models of vaginal challenge. J Virol 80 9 (2006) 4447-4457
46. Reuter J.D., Vivas-Gonzalez B.E., Gomez D., Wilson J.H., Brandsma J.L., Greenstone H.L., et al. Intranasal vaccination with a recombinant vesicular stomatitis virus expressing cottontail rabbit papillomavirus L1 protein provides complete protection against papillomavirus-induced disease. J Virol 76 17 (2002) 8900-8909
47. Roberts A., Reuter J.D., Wilson J.H., Baldwin S., and Rose J.K. Complete protection from papillomavirus challenge after a single vaccination with a vesicular stomatitis virus vector expressing high levels of L1 protein. J Virol 78 6 (2004) 3196-3199
48. Schlereth B., Rose J.K., Buonocore L., ter Meulen V., and Niewiesk S. Successful vaccine-induced seroconversion by single-dose immunization in the presence of measles virus-specific maternal antibodies. J Virol 74 10 (2000) 4652-4657
49. Schnell M.J., Johnson J.E., Buonocore L., and Rose J.K. Construction of a novel virus that targets HIV-1-infected cells and controls HIV-1 infection. Cell 90 5 (1997) 849-857
50. Schwartz J.A., Buonocore L., Roberts A., Suguitan Jr. A., Kobasa D., Kobinger G., et al. Vesicular stomatitis virus vectors expressing avian influenza H5 HA induce cross-neutralizing antibodies and long-term protection. Virology 366 1 (2007) 166-173
51. Ramsburg E., Publicover J., Buonocore L., Poholek A., Robek M., Palin A., et al. A vesicular stomatitis virus recombinant expressing granulocyte-macrophage colony-stimulating factor induces enhanced T-cell responses and is highly attenuated for replication in animals. J Virol 79 24 (2005) 15043-15053
52. Fuerst T.R., Niles E.G., Studier F.W., and Moss B. Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. Proc Natl Acad Sci USA 83 21 (1986) 8122-8126
53. Iverson L.E., and Rose J.K. Localized attenuation and discontinuous synthesis during vesicular stomatitis virus transcription. Cell 23 2 (1981) 477-484
54. Bashaw J., Norris S., Weeks S., Trevino S., Adamovicz J.J., and Welkos S. Development of in vitro correlate assays of immunity to infection with Yersinia pestis. Clin Vaccine Immunol 14 5 (2007) 605-616
55. Parent M.A., Berggren K.N., Kummer L.W., Wilhelm L.B., Szaba F.M., Mullarky I.K., et al. Cell-mediated protection against pulmonary Yersinia pestis infection. Infect Immun 73 11 (2005) 7304-7310
56. Philipovskiy A.V., and Smiley S.T. Vaccination with live Yersinia pestis primes CD4 and CD8 T cells that synergistically protect against lethal pulmonary Y. pestis infection. Infect Immun 75 2 (2007) 878-885
57. Shim H.K., Musson J.A., Harper H.M., McNeill H.V., Walker N., Flick-Smith H., et al. Mechanisms of major histocompatibility complex class II-restricted processing and presentation of the V antigen of Yersinia pestis. Immunology 119 3 (2006) 385-392
58. Kerksiek K.M., and Pamer E.G. T cell responses to bacterial infection. Curr Opin Immunol 11 4 (1999) 400-405
59. Schroder K., Hertzog P.J., Ravasi T., and Hume D.A. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 75 2 (2004) 163-189
60. Pilione M.R., and Harvill E.T. The Bordetella bronchiseptica type III secretion system inhibits gamma interferon production that is required for efficient antibody-mediated bacterial clearance. Infect Immun 74 2 (2006) 1043-1049
61. Malley R., Trzcinski K., Srivastava A., Thompson C.M., Anderson P.W., and Lipsitch M. CD4+ T cells mediate antibody-independent acquired immunity to pneumococcal colonization. Proc Natl Acad Sci USA 102 13 (2005) 4848-4853
62. Elvin S.J., and Williamson E.D. Stat 4 but not Stat 6 mediated immune mechanisms are essential in protection against plague. Microb Pathog 37 4 (2004) 177-184
63. Nakajima R., and Brubaker R.R. Association between virulence of Yersinia pestis and suppression of gamma interferon and tumor necrosis factor alpha. Infect Immun 61 1 (1993) 23-31